ASSESSMENT OF PRE- AND POST-OPERATIVE VALUES OF ERYTHROCYTES, HEMOGLOBIN, HEMATOCRIT AND DRAINAGE VOLUME AFTER ADMINISTRATION OF TRANEXAMIC ACID IN TOTAL HIP ARTHROPLASTY
Keywords:
hip arthroplasty, tranexamic acid, osteoarthritis, blood loss, blood transfusionAbstract
Total hip arthroplasty is a well-established and effective treatment for hip osteoarthritis. However, it is commonly associated with significant blood loss and an increased need for blood transfusions. Tranexamic acid, an antifibrinolytic agent, prevents the degradation of fibrin and preserves the integrity of the fibrin matrix. This study aimed to assess the pre- and postoperative levels of erythrocytes, hemoglobin, hematocrit, and drainage volume following intravenous administration of tranexamic acid during total hip arthroplasty.
A total of 40 patients participated in the study, divided into two groups: an experimental group receiving intravenous tranexamic acid and a control group not receiving the drug.
On the second postoperative day, the experimental group showed a smaller decrease in erythrocytes (0.2935 x 10¹²/L), hemoglobin (11.093 g/L), and hematocrit (0.032) compared to the control group. Furthermore, the total drainage volume from the day of surgery and the first postoperative day was reduced by 137.65 ml in the experimental group.
Overall, the use of tranexamic acid proved to be a safe and effective strategy for minimizing postoperative declines in erythrocyte, hemoglobin, and hematocrit levels, while also reducing postoperative drainage volume. This ultimately leads to decreased blood loss and a lower requirement for blood transfusions.
References
Räsänen P, Paavolainen P, Sintonen H, Koivisto AM, Blom M, Ryynänen OP, et al. Effectiveness of hip or knee replacement surgery in terms of quality-adjusted life years and costs. ActaOrthop 2007; 78(1): 108-115. doi: 10.1080/17453670610013501.
Learmonth ID, Young C, Rorabeck C. The operation of the century: total hip replacement. Lancet 2007; 370(9597): 1508-1519. doi: 10.1016/S0140-6736(07)60457-7.
Vuille-Lessard E, Boudreault D, Girard F, Ruel M, Chagnon M, Hardy JF. Red blood cell transfusion practice in elective orthopedic surgery: a multicenter cohort study. Transfusion 2010; 50(10): 2117-2124. doi: 10.1111/j.1537-2995.2010.02697.x.
Hays MB, Mayfield JF. Total blood loss in major joint arthroplasty. A comparison of cemented and noncemented hip and knee operations. J Arthroplasty 1988; 3 Suppl: S47-9. doi: 10.1016/s0883-5403(88)80008-1.
Sehat KR, Evans RL, Newman JH. Hidden blood loss following hip and knee arthroplasty. Correct management of blood loss should take hidden loss into account. J Bone Joint Surg Br 2004; 86(4): 561-565. PMID: 15174554.
Billote DB, Glisson SN, Green D, Wixson RL. A prospective, randomized study of preoperative autologous donation for hip replacement surgery. J Bone Joint Surg Am 2002; 84(8): 1299-1304. doi: 10.2106/00004623-200208000-00002.
Charrois O, Kahwaji A, Vastel L, Rosencher N, Courpied JP. Blood loss in total hip arthroplasty for rapidly destructive coxarthrosis. IntOrthop 2001; 25(1): 22-24. doi: 10.1007/s002640000210.
Stanworth SJ, Cockburn HA, Boralessa H, Contreras M. Which groups of patients are transfused? A study of red cell usage in London and southeast England. Vox Sang 2002; 83(4): 352-357. doi: 10.1046/j.1423-0410.2002.00237.x.
Jans Ø, Kehlet H, Hussain Z, Johansson PI. Transfusion practice in hip arthroplasty-a nationwide study. Vox Sang 2011; 100(4): 374-380. doi: 10.1111/j.1423-0410.2010.01428.x.
Browne JA, Adib F, Brown TE, Novicoff WM. Transfusion rates are increasing following total hip arthroplasty: risk factors and outcomes. J Arthroplasty 2013; 28(8 Suppl): 34-37. doi: 10.1016/j.arth.2013.03.035.
Spiess BD. Transfusion of blood products affects outcome in cardiac surgery. Semin Cardiothorac Vasc Anesth 2004; 8(4): 267-281. doi: 10.1177/108925320400800402.
Rawn J. The silent risks of blood transfusion. CurrOpinAnaesthesiol 2008; 21(5): 664-668. doi: 10.1097/ACO.0b013e32830f1fd1.
Taneja A, El-Bakoury A, Khong H, Railton P, Sharma R, Johnston KD, et al. Association between Allogeneic Blood Transfusion and Wound Infection after Total Hip or Knee Arthroplasty: A Retrospective Case-Control Study. J Bone Jt Infect 2019; 4(2): 99-105. doi: 10.7150/jbji.30636.
Juraj M, Jaroslav V, Gažová A, Žufková V, Kyselovič J, Šteňo B. Evaluation of efficacy and safety of systemic and topical intra-articular administration of tranexamic acid in primary unilateral total hip arthroplasty. Medicine (Baltimore) 2021; 100(26): e26565. doi: 10.1097/MD.0000000000026565.
Nilsson IM. Clinical pharmacology of aminocaproic and tranexamic acids. J ClinPatholSuppl (R CollPathol). 1980; 14: 41-47. PMID: 7000846.
Cai J, Ribkoff J, Olson S, Raghunathan V, Al-Samkari H, DeLoughery TG, et al. The many roles of tranexamic acid: An overview of the clinical indications for TXA in medical and surgical patients. Eur J Haematol 2020; 104(2): 79-87. doi: 10.1111/ejh.13348.
Wei W, Wei B. Comparison of topical and intravenous tranexamic acid on blood loss and transfusion rates in total hip arthroplasty. J Arthroplasty 2014; 29(11): 2113-2116. doi: 10.1016/j.arth.2014.07.019.
Ekbäck, Gustav MD*; Axelsson, Kjell MD, PhD*; Ryttberg, Lars MD†; Edlund, Bror MD, PhD‡; Kjellberg, Jill Chief CRNA*; Weckström, Johan MD†; Carlsson, Olle PhD§; Schött, Ulf MD, PhD*. Tranexamic Acid Reduces Blood Loss in Total Hip Replacement Surgery. Anesthesia & Analgesia 2000; 91(5): 1124-1130. doi: 10.1213/00000539-200011000-00014.
